James Hollingshead

Former President, Chief Executive Officer & Director, Insulet

Search every verified James Hollingshead interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. James Hollingshead, CEO of Insulet, discussed the company’s recent earnings and outlook in a November 2024 interview. He noted that Insulet raised its annual revenue growth forecast to 20–21%, up from a prior range of 16–19%, following better-than-expected results. He also mentioned the company’s recent launch of an app for its Omnipod insulin pump for iPhone users. Regarding GLP-1 drugs, Hollingshead said they are effective for glycemic control but do not cure type 2 diabetes, and that many patients eventually require insulin therapy. He described the U.S. market for type 2 diabetes patients using insulin as large, with about six million people, and said such patients could still benefit from Insulet’s Omnipod 5 product. On policy, he said lowering insulin costs is beneficial to both customers and the company, and he declined to speculate on the regulatory environment under the incoming Trump administration, stating that Insulet’s position is robust given the increasing prevalence of diabetes.